Lonza Group AG Logo

Lonza Group AG

A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.

LONN | SW

Overview

Corporate Details

ISIN(s):
CH0013841017 (+2 more)
LEI:
549300EFW4H2TCZ71055
Country:
Switzerland
Address:
MÜNCHENSTEINERSTR. 38, 4052 BASEL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lonza Group AG is a Swiss multinational company and a leading global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotechnology, and nutrition industries. The company provides integrated services that span from early-stage development to the commercial manufacturing of drug substances and drug products. Lonza specializes in a wide range of advanced technologies, including mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), bioconjugates, mRNA, and cell and gene therapies. Founded in 1897, Lonza leverages its extensive scientific and manufacturing expertise to enable its customers to bring innovative and life-enhancing therapies to market for patients worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-03 09:00
Board/Management Information
Lonza Nominates Claudia Sussmuth-Dyckerhoff as Board Member
English 17.8 KB
2025-10-03 02:00
Board/Management Information
Lonza Nominates Claudia Süssmuth-Dyckerhoff as Board Member
English 14.2 KB
2025-09-12 09:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 22.8 KB
2025-09-12 02:00
Board/Management Information
Lonza Appoints Jason Berndt as Head of Group Operations, and Maria Soler Nunez …
English 18.8 KB
2025-07-23 06:30
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 42.2 KB
2025-07-23 02:00
Earnings Release
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sale…
English 37.0 KB
2025-07-23 02:00
Earnings Release
Lonza erzielt starkes Ergebnis im ersten Halbjahr 2025 und erhöht Umsatz- und M…
German 36.9 KB
2025-05-27 07:00
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 12.7 KB
2025-05-27 02:00
Regulatory News Service
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
English 9.7 KB
2025-05-15 09:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 14.6 KB
2025-05-15 02:00
Board/Management Information
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
English 11.0 KB
2025-05-10 16:30
Post-Annual General Meeting Information
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
English 16.3 KB
2025-05-09 06:30
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 15.2 KB
2025-05-09 02:00
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
English 12.5 KB
2025-04-03 07:00
Report Publication Announcement
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual a…
English 20.1 KB

Automate Your Workflow. Get a real-time feed of all Lonza Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Lonza Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 N/A Executive member Buy None 147,442.00 CHF
2025-03-13 N/A Executive member Buy None 107,906.00 CHF
2025-03-12 N/A Executive member Buy None 146,239.00 CHF
2025-03-11 N/A Executive member Buy None 382,476.00 CHF
2025-03-10 N/A Executive member Buy None 771,722.40 CHF
2025-03-07 N/A Executive member Buy None 338,476.00 CHF
2025-03-06 N/A Executive member Buy None 313,416.00 CHF
2025-02-18 N/A Executive member Buy None 164,554.00 CHF
2025-02-14 N/A Executive member Buy None 130,606.00 CHF
2025-02-13 N/A Executive member Buy None 29,500.00 CHF

Peer Companies

Company Country Ticker View
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan 4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland KNRS
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan 4547

Talk to a Data Expert

Have a question? We'll get back to you promptly.